Franklin Street Advisors Inc. NC Buys 20,000 Shares of Calithera Biosciences Inc (CALA)

Franklin Street Advisors Inc. NC increased its stake in Calithera Biosciences Inc (NASDAQ:CALA) by 56.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 55,580 shares of the biotechnology company’s stock after buying an additional 20,000 shares during the quarter. Franklin Street Advisors Inc. NC’s holdings in Calithera Biosciences were worth $464,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. FMR LLC grew its stake in shares of Calithera Biosciences by 85.8% in the second quarter. FMR LLC now owns 2,717,090 shares of the biotechnology company’s stock valued at $40,349,000 after buying an additional 1,254,900 shares in the last quarter. State Street Corp grew its stake in shares of Calithera Biosciences by 5,802.1% in the second quarter. State Street Corp now owns 1,304,375 shares of the biotechnology company’s stock valued at $19,370,000 after buying an additional 1,282,275 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Calithera Biosciences by 29.7% in the second quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock valued at $17,813,000 after buying an additional 274,510 shares in the last quarter. Lord Abbett & CO. LLC grew its stake in shares of Calithera Biosciences by 65.5% in the second quarter. Lord Abbett & CO. LLC now owns 497,811 shares of the biotechnology company’s stock valued at $7,392,000 after buying an additional 197,055 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Calithera Biosciences by 272.8% in the third quarter. American Century Companies Inc. now owns 424,752 shares of the biotechnology company’s stock valued at $6,690,000 after buying an additional 310,806 shares in the last quarter. Institutional investors and hedge funds own 72.19% of the company’s stock.

Shares of Calithera Biosciences Inc (NASDAQ CALA) opened at $8.68 on Thursday. Calithera Biosciences Inc has a 12 month low of $4.00 and a 12 month high of $20.05. The firm has a market capitalization of $308.65, a P/E ratio of -8.77 and a beta of 2.87.

Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $7.20 million for the quarter, compared to analyst estimates of $6.02 million. research analysts forecast that Calithera Biosciences Inc will post -0.77 earnings per share for the current year.

CALA has been the subject of a number of recent research reports. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Monday, November 6th. BidaskClub lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 9th. ValuEngine lowered Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, William Blair started coverage on Calithera Biosciences in a research note on Thursday, October 5th. They set an “outperform” rating for the company. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. Calithera Biosciences presently has an average rating of “Hold” and a consensus target price of $15.17.

WARNING: This piece of content was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/11/franklin-street-advisors-inc-nc-buys-20000-shares-of-calithera-biosciences-inc-cala.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences Inc (NASDAQ:CALA).

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply